These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33651097)

  • 1. Paying for Prescription Drugs in the New Administration.
    Kesselheim AS; Hwang TJ; Avorn J
    JAMA; 2021 Mar; 325(9):819-820. PubMed ID: 33651097
    [No Abstract]   [Full Text] [Related]  

  • 2. The Burden of Federalism: Challenges to State Attempts at Controlling Prescription Drug Costs.
    Gudiksen KL; King JS
    J Leg Med; 2019; 39(2):95-120. PubMed ID: 31503534
    [No Abstract]   [Full Text] [Related]  

  • 3. An Incomplete Prescription: President Trump's Plan to Address High Drug Prices.
    Sarpatwari A; Avorn J; Kesselheim AS
    JAMA; 2018 Jun; 319(23):2373-2374. PubMed ID: 29800027
    [No Abstract]   [Full Text] [Related]  

  • 4. The Price of Crossing the Border for Medications.
    Fralick M; Avorn J; Kesselheim AS
    N Engl J Med; 2017 Jul; 377(4):311-313. PubMed ID: 28745989
    [No Abstract]   [Full Text] [Related]  

  • 5. US lawmakers seek cuts in prescription drug prices.
    Jaffe S
    Lancet; 2019 Mar; 393(10175):975-976. PubMed ID: 30860040
    [No Abstract]   [Full Text] [Related]  

  • 6. Medicare and drug pricing.
    Iglehart JK
    N Engl J Med; 2003 Apr; 348(16):1590-7. PubMed ID: 12700381
    [No Abstract]   [Full Text] [Related]  

  • 7. A New Way to Contain Unaffordable Medication Costs - Exercising the Government's Existing Rights.
    Engelberg AB; Avorn J; Kesselheim AS
    N Engl J Med; 2022 Mar; 386(12):1104-1106. PubMed ID: 35139270
    [No Abstract]   [Full Text] [Related]  

  • 8. The Pay-Twice Critique, Government Funding, and Reasonable Pricing Clauses.
    Wolitz RE
    J Leg Med; 2019; 39(2):177-211. PubMed ID: 31503531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescription-drug prices.
    Frank RG
    N Engl J Med; 2004 Sep; 351(14):1375-7. PubMed ID: 15459294
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug Costs: The Controversy Continues.
    Lipman AG
    J Pain Palliat Care Pharmacother; 2017 Mar; 31(1):2-3. PubMed ID: 28287362
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmaceutical Policy Reform--Balancing Affordability with Incentives for Innovation.
    Conti RM; Rosenthal MB
    N Engl J Med; 2016 Feb; 374(8):703-6. PubMed ID: 26933845
    [No Abstract]   [Full Text] [Related]  

  • 12. Can price and regulatory controls replace free market competition in the drug industry?
    Buc NL; Levitt GM
    Healthspan; 1993 Nov; 10(10):30-2. PubMed ID: 10130839
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmac dogma.
    Douglas B
    N Z Med J; 2007 Feb; 120(1249):U2430. PubMed ID: 17308566
    [No Abstract]   [Full Text] [Related]  

  • 14. States' Rx for drug costs.
    Cauchi R
    State Legis; 2001 Jan; 27(1):20-1, 23. PubMed ID: 11708349
    [No Abstract]   [Full Text] [Related]  

  • 15. Opinion: price controls on prescription drugs.
    Franks B
    N J Med; 2004 Apr; 101(4):56, 55. PubMed ID: 15103791
    [No Abstract]   [Full Text] [Related]  

  • 16. The States as Important Laboratories for Federal Prescription Drug Cost-Containment Efforts.
    Horvath JC; Anderson GF
    JAMA; 2019 Apr; 321(16):1561-1562. PubMed ID: 31012941
    [No Abstract]   [Full Text] [Related]  

  • 17. Medicare and prescription drugs.
    Iglehart JK
    N Engl J Med; 2001 Mar; 344(13):1010-5. PubMed ID: 11274630
    [No Abstract]   [Full Text] [Related]  

  • 18. Prescription Drugs-List Price, Net Price, and the Rebate Caught in the Middle.
    Dusetzina SB; Bach PB
    JAMA; 2019 Apr; 321(16):1563-1564. PubMed ID: 30840047
    [No Abstract]   [Full Text] [Related]  

  • 19. Regulating Drug Prices while Increasing Innovation.
    Conti RM; Frank RG; Gruber J
    N Engl J Med; 2021 Nov; 385(21):1921-1923. PubMed ID: 34767322
    [No Abstract]   [Full Text] [Related]  

  • 20. The unintended consequences of the 340B safety-net drug discount program.
    Thomas S; Schulman K
    Health Serv Res; 2020 Apr; 55(2):153-156. PubMed ID: 32114714
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.